COVID-19 / Coronavirus

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

2022-12-14 15:17 3889

TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...

CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients

2022-12-14 12:36 2297

BEIJING, Dec. 14, 2022 /PRNewswire/ -- To echo China's new guidelines for COVID-19 prevention and control, local governments and hospitals across the country have been optimizing medical services and the allocation of medical resources to face a likely surge in patients and take better care of th...

Fosun International Receives "ESG Leading Enterprise Award" and "ESG Leading Social Initiative Award" from Bloomberg Businessweek/Chinese Edition

2022-12-14 11:09 2880

HONG KONG, Dec. 14, 2022 /PRNewswire/ -- On 12 December 2022, the results of the fourth ESG Leading Enterprise Awards 2022, which was organized by the Chinese Edition of Bloomberg Businessweek in partnership with Deloitte, one of the world's largest accounting firms, and with the support from Inv...

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

2022-12-14 01:41 3614

GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

2022-12-14 01:40 1945

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

CGTN: The Chinese are sharing their COVID experiences as policy optimized

2022-12-13 12:49 2082

BEIJING, Dec. 13, 2022 /PRNewswire/ -- Vincent Zhong is a Chinese digital gadget YouTuber with more than 372,000 followers. Aside from smartphones, earbuds and laptops, Zhong recently unboxed a special object: COVID-19. "I'm screwed," Zhong said in a video showing a positive COVID test result on ...

Epidemic: Modified approach ensures maximum benefit

2022-12-13 11:42 1485

BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from chinadaily.com.cn: After three years of battling COVID-19, experts said China is seeing the light at the end of the tunnel as it continues to optimize measures against the epidemic.

Youth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights

2022-12-13 10:07 2413

Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against ...

CSL Announces Next CEO & Managing Director

2022-12-13 07:23 3154

Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...

Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19

2022-12-12 23:29 3600

--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data ...

CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation

2022-12-12 15:39 2264

BEIJING, Dec. 12, 2022 /PRNewswire/ -- Under the Belt and Road Initiative (BRI), China-Arab cooperation in the fields of infrastructure, space and health has been continuously developed in a sustainable manner. China has vowed to ...

China further optimizes COVID-19 response with new measures

2022-12-12 11:38 1922

BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from People's Daily: Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by the country on further optimizing the COVID-19 response, so as to contain the epidemi...

China recalibrates its COVID-19 response strategy

2022-12-12 10:22 1779

BEIJING, Dec. 12, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn onDecember 7 that they would no longer be required to take the ...

Asia embraces the dawn

2022-12-10 00:31 9128

HONG KONG, Dec. 10, 2022 /PRNewswire/ -- A photo exhibition that captures the changes in Asian people's daily lives under the COVID-19 pandemic and encourages people to move forward opened inHong Kong on Friday. Co-organized by China Daily and the Asia News Network, the Changing Asia – New Norma...

CGTN: What has China done in its nearly 3 years of COVID-19 fight?

2022-12-09 16:30 2318

BEIJING, Dec. 9, 2022 /PRNewswire/ -- It's been nearly three years since China launched the fight against COVID-19. During that time,China's relentless efforts protected its people and provided valuable experiences for the world. The efforts also bought precious time to develop a scientific way t...

Amway launches Singapore Business Innovation Hub to accelerate health and wellness innovation

2022-12-08 09:30 3349

Hub launched in partnership with the Economic Development Board to serve as a springboard for product innovation to meet consumers' evolving wellness needs globally and also uniquely inAsia, backed by science and technology SINGAPORE, Dec. 8, 2022 /PRNewswire/ -- Amway, an entrepreneur-led he...

BSR KOREA Introduces "Wizbiosolutions Inc." as "2022 Global Procurement Marketer"

2022-12-08 00:00 2395

SEOUL, South Korea, Dec. 7, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

2022-12-07 18:10 2666

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ...

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

2022-12-06 21:01 2123

* Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization inthe United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world includingChina. * ...

University of Tokyo and Sekisui House Launch Joint Research on Biodiversity and Health

2022-12-06 14:00 1731

TOKYO, Dec. 6, 2022  /PRNewswire/ -- - World's First Research into Relationship between Rich-in-Biodiversity Garden Greenery and Health/Well-being - The University of Tokyo's Graduate School of Agricultural and Life Sciences (GSALS) and Sekisui House, Ltd. launched a joint research project on b...

1 ... 21222324252627 ... 226